AZD8701,一种针对FOXP3mRNA的反意义寡核酸,作为单疗法和与杜尔瓦卢马布联合使用:在患有高级固体瘤的患者中进行I期试验

Lillian L Siu1, Sophie Postel-Vinay2, Rafael Villanueva-Vázquez3

  • 1Princess Margaret Cancer Centre, Toronto, Canada.

概括

这一第一阶段研究表明,针对FOXP3的抗意义寡核酸AZD8701在先进的固体瘤中具有临床可行性. 该疗法证明了可管理的安全性和成功地传递给瘤,支持进一步研究这种新型免疫疗法方法.

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...